



EXHIBIT A
MARSHALL VERSION OF THE CLAIMS
U.S. PATENT APPLICATION NO. 09/500,397

RECEIVED

JUL 11 2002

TECH CENTER 1600/2900

Matter that has been deleted from the claims is indicated by brackets and matter that has been added is indicated by underlining:

-19. (twice amended) A method of treating an angiogenic disease comprising administering to an animal suffering from such a disease [an] a therapeutically effective amount of [a] plasminogen activator effective to [convert plasminogen to plasmin and optionally an amount of a sulfhydryl donor effective to cause the conversion plasmin to angiostatin] increase the amount of angiostatin present in said animal to treat the angiogenic disease.

20. (once amended) The method of Claim 19 [wherein the] further comprising administering a sulfhydryl donor [is] selected from the group consisting of cysteine, N-acetyl cysteine, captopril, D-penicillamine and reduced glutathione.

21. (once amended) The method of Claim 19 wherein an [effective] amount of plasmin is also administered to the animal.

24. (once amended) The method of Claim 19 wherein an [effective] amount of plasminogen is also administered to the animal.

76. (new) The method of Claim 19 wherein said animal is a human.

77. (new) The method of Claim 19 wherein said angiogenic disease is a neoplastic disease.

78. (new) The method of Claim 77 wherein the neoplastic disease is a malignant tumor.

79. (new) The method of Claim 77 wherein the neoplastic disease is a benign tumor.

80. (new) A method of treating an angiogenic disease comprising administering to an animal suffering from such a disease a therapeutically effective amount of a plasminogen activator and a sulfhydryl donor effective to increase the amount of angiostatin present in said animal to treat the angiogenic disease.

81. (new) The method of Claim 80 wherein the sulfhydryl donor is selected from the group consisting of cysteine, N-acetyl cysteine, captopril, D-penicillamine and reduced glutathione.

82. (new) The method of Claim 80 wherein the plasminogen activator is selected from the group consisting of urokinase, streptokinase and tissue plasminogen activator.

83. (new) The method of Claim 80 further comprising administering plasminogen.

84. (new) The method of Claim 80 further comprising administering plasmin.

85. (new) The method of Claim 80 wherein said animal is a human.

86. (new) The method of Claim 80 wherein said angiogenic disease is a neoplastic disease.

87. (new) The method of Claim 86 wherein the neoplastic disease is a malignant tumor.

88. (new) The method of Claim 86 wherein the neoplastic disease is a benign tumor--